Document Detail


Pre- and post-treatment distribution pattern of 123I-MIBG in patients with phaeochromocytomas and paragangliomas.
MedLine Citation:
PMID:  2812639     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
123I-metaiodobenzylguanidine (MIBG) localizes in adrenergic neurones. A comparison of % washout of MIBG, during two time intervals, from various organs was carried out in seven normal volunteers and 11 patients with phaeochromocytoma and/or paraganglioma pre- and post-treatment using MIBG. % washout of MIBG during the time intervals of 30 min to 4 h were as follows: heart, controls 26.1 +/- 3.8 v. patients 51.5 +/- 9.1, (p less than 0.001), lungs, controls 36.5 +/- 5.3 v. patients 47.3 +/- 5.8, (p less than 0.05), liver, controls 26.5 +/- 5.7 v. patients 53.4 +/- 12.0 (p less than 0.01). Following treatment the % washout of MIBG from these tissues between 30 min and 4 h were similar in both groups of subjects. This observation coincided with the normalization of plasma catecholamine levels in most of the treatment group. There was no significant difference between the treatment and control groups, in the % washout of MIBG from these tissues during the 4 h and 22 h time intervals either before or after treatment. We conclude that quantitative scintigraphy 30 min to 4 h after MIBG administration is a useful technique to evaluate the pathophysiological effects of high circulating catecholamines in patients with phaeochromocytomas and/or paragangliomas.
Authors:
A J Sinclair; J Bomanji; P Harris; G Ross; G M Besser; K E Britton
Related Documents :
2036229 - The value of transesophageal echocardiography in children with congenital heart disease.
8076119 - Right atrial isolation associated with atrial septal closure in patients with atrial se...
8854329 - Electrophysiologic differences in young patients with atrial fibrillation. influence of...
11092099 - Anticoagulants.
7743009 - Low-energy internal cardioversion for atrial fibrillation resistant to external cardiov...
16881979 - Patent foramen ovale using the premere device: the results of the closeup trial.
9686959 - Therapy of focal and segmental glomerulosclerosis with methylprednisolone, cyclosporine...
715039 - Loss of silicone implants after subcutaneous mastectomy and reconstruction.
16126979 - Nocturnal hormones and clinical rhythms in rheumatoid arthritis.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Nuclear medicine communications     Volume:  10     ISSN:  0143-3636     ISO Abbreviation:  Nucl Med Commun     Publication Date:  1989 Aug 
Date Detail:
Created Date:  1989-12-21     Completed Date:  1989-12-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8201017     Medline TA:  Nucl Med Commun     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  567-76     Citation Subset:  IM    
Affiliation:
Medical College of St. Bartholomew's Hospital, Department of Nuclear Medicine and Endocrinology, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
3-Iodobenzylguanidine
Adrenal Gland Neoplasms / metabolism,  radionuclide imaging*
Adult
Catecholamines / metabolism
Female
Humans
Iodine Radioisotopes / diagnostic use,  pharmacokinetics*,  therapeutic use
Iodobenzenes / pharmacokinetics*,  therapeutic use
Male
Metabolic Clearance Rate
Middle Aged
Paraganglioma / metabolism,  radionuclide imaging*,  therapy
Pheochromocytoma / metabolism,  radionuclide imaging*,  therapy
Tissue Distribution
Chemical
Reg. No./Substance:
0/Catecholamines; 0/Iodine Radioisotopes; 0/Iodobenzenes; 77679-27-7/3-Iodobenzylguanidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical evaluation of angiotensin II enhanced perfusion scintigraphy in metastatic liver disease.
Next Document:  Intraperitoneal 131I- and 111In-791T/36 monoclonal antibody in recurrent ovarian cancer: imaging and...